Antipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in Japan: a health care database analysis

References

• LehmanAFLiebermanJADixonLBPractice guideline for the treatment of patients with schizophrenia, 2nd edAm J Psychiatry2004161Suppl 2115000267
   PubMed Web of Science ®Google Scholar
• RittmannsbergerHMeiseUSchauflingerKHorvathEDonatHHinterhuberHPolypharmacy in psychiatric treatment: patterns of psychotropic drug use in Austrian psychiatric clinicsEur Psychiatry1999141334010572323
   PubMed Web of Science ®Google Scholar
• WilliamsCLJohnstoneBMKestersonJGJavorKASchmetzerADEvaluation of antipsychotic and concomitant medication use patterns in patients with schizophreniaMed Care1999374 Suppl LillyAS818610217396
   PubMed Web of Science ®Google Scholar
• MillierASarlonEAzorinJMRelapse according to antipsychotic treatment in schizophrenic patients: a propensity-adjusted analysisBMC Psychiatry2011112421314943
   PubMed Web of Science ®Google Scholar
• SchumacherJEMakelaEHGriffinHRMultiple antipsychotic medication prescribing patternsAnn Pharmacother2003377–895195512841799
   PubMed Web of Science ®Google Scholar
• TappAWoodAESecrestLErdmannJCubberleyLKilziehNCombination antipsychotic therapy in clinical practicePsychiatr Serv2003541555912509667
   PubMed Web of Science ®Google Scholar
• GangulyRKotzanJAMillerLSKennedyKMartinBCPrevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998–2000J Clin Psychiatry200465101377138815491242
   PubMed Web of Science ®Google Scholar
• GhaemiSN“All the worse for the fishes”: conceptual and historical background of polypharmacy in psychiatryGhaemiSNPolypharmacy in PsychiatryNew York (NY)Marcel Dekker2002134
   Google Scholar
• OepenGPolypharamcy in schizophreniaGhaemiSNPolypharmacy in PsychiatryNew York (NY)Marcel Dekker2002101132
   Google Scholar
• CorrellCUAntipsychotic polypharmacy, part 1: shotgun approach or targeted cotreatment?J Clin Psychiatry200869467467518507487
   PubMed Web of Science ®Google Scholar
• BarnesTRPatonCAntipsychotic polypharmacy in schizophrenia: benefits and risksCNS Drugs201125538339921476610
   PubMed Web of Science ®Google Scholar
• FreudenreichOGoffDCAntipsychotic combination therapy in schizophrenia: a review of efficacy and risks of current combinationsActa Psychiatr Scand2002106532333012366465
   PubMed Web of Science ®Google Scholar
• AdvokatCDixonDSchneiderJComatyJEJrComparison of risperidone and olanzapine as used under “real-world” conditions in a state psychiatric hospitalProg Neuropsychopharmacol Biol Psychiatry200428348749515093956
   PubMed Web of Science ®Google Scholar
• MillerALCraigCSCombination antipsychotics: pros, cons, and questionsSchizophr Bull200228110510912047009
   PubMed Web of Science ®Google Scholar
• LoosbrockDLZhaoZJohnstoneBMMorrisLSAntipsychotic medication use patterns and associated costs of care for individuals with schizophreniaJ Ment Health Policy Econ200362677514578539
   PubMedGoogle Scholar
• JaffeABLevineJAntipsychotic medication coprescribing in a large state hospital systemPharmacoepidemiol Drug Saf2003121414812616846
   PubMed Web of Science ®Google Scholar
• ZhuBAscher-SvanumHFariesDECorrellCUKaneJMCost of antipsychotic polypharmacy in the treatment of schizophreniaBMC Psychiatry200881918394168
   PubMed Web of Science ®Google Scholar
• RupnowMFGreenspanAKosik-GonzalezCZhuYGarawabiGStahlSMUse and cost of polypharmacy in schizophrenia: data from a randomized double-blind study of risperidone and quetiapineValue Health20058399
   Web of Science ®Google Scholar
• StahlSMAntipsychotic polypharmacy: squandering precious resources?J Clin Psychiatry2002632939411874226
   PubMed Web of Science ®Google Scholar
• ProcyshynRMKennedyNBTseGThompsonBAntipsychotic polypharmacy: a survey of discharge prescriptions from a tertiary care psychiatric institutionCan J Psychiatry200146433433911387789
   PubMed Web of Science ®Google Scholar
• ClarkREBartelsSJMellmanTAPeacockWJRecent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorders: implications for state mental health policySchizophr Bull2002281758412047024
   PubMed Web of Science ®Google Scholar
• CovellNHJacksonCTEvansACEssockSMAntipsychotic prescribing practices in Connecticut’s public mental health system: rates of changing medications and prescribing stylesSchizophr Bull2002281172912047017
   PubMed Web of Science ®Google Scholar
• JerrellJMCost-effectiveness of risperidone, olanzapine, and conventional antipsychotic medicationsSchizophr Bull200228458960512795493
   PubMed Web of Science ®Google Scholar
• CentorrinoFGorenJLHennenJSalvatorePKelleherJPBaldessariniRJMultiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefitsAm J Psychiatry2004161470070615056517
   PubMed Web of Science ®Google Scholar
• YoshiTKurosawaMSugimuraKCurrent status of the psychopharmacological treatment of schizophrenic patients in Japan: from 2005 nationwide survey of 9 psychiatric hospitals in the psychiatric clinical pharmacy societyJpn J Clin Psychopharmacol20071017211731
   Google Scholar
• YoshiTUnoJNakagawaMSurvey of the prescription for psychotherapy in Japanese inpatients with schizophrenia in 2006Jpn J Clin Psychopharmacol20101315351545
   Google Scholar
• FariesDAscher-SvanumHZhuBCorrellCKaneJAntipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychoticsBMC Psychiatry200552615921508
   PubMed Web of Science ®Google Scholar
• BitterIChouJCUngvariGSPrescribing for inpatients with schizophrenia: an international multi-center comparative studyPharmacopsychiatry200336414314912905100
   PubMed Web of Science ®Google Scholar
• CorrellCUKaneJMO’SheaDRaziKMalhotraAKAntipsychotic polypharmacy in the treatment of schizophreniaSchizophr Res2003601 Suppl 1S37
   Web of Science ®Google Scholar
• WangPFZhaoZComparison of olanzapine versus quetiapine in the treatment of hospitalized patients with schizophreniaValue Health20036355
   Web of Science ®Google Scholar
• CorrellCUFredericksonAMKaneJMManuPDoes antipsychotic polypharmacy increase the risk for metabolic syndrome?Schizophr Res2007891–39110017070017
   PubMed Web of Science ®Google Scholar
• NovickDAscher-SvanumHBrugnoliRBertschJHongJHaroJMAntipsychotic monotherapy treatment with atypicals in outpatients with schizophrenia: results from a naturalistic observational studySchizophr Bull201137Suppl 1S316317
   Google Scholar
• YoshimuraROkamotoTNakamuraJPrescription pattern of antipsychotic drugs for schizophrenic inpatients in Japan: research on East Asia Psychotropic Prescription Pattern-Antipsychotics studyPsychiatry Clin Neurosci200660677877917109719
   PubMed Web of Science ®Google Scholar
• World Health OrganizationInternational Statistical Classification of Diseases and Related Health Problems 10th Revision version for 20072nd ed2007 Available from: http://apps.who.int/classifications/apps/icd/icd10online2007/Accessed January 20, 2011
   Google Scholar
• World Health OrganizationCollaborating Centre for Drug Statistics MethodologyWorld Health Organization Anatomical Therapeutic Chemical (ATC) classification index including defined daily doses (DDDs)Oslo, NorwayWorld Health Organization Collaborating Centre for Drug Statistics Methodology Available from: http://www.whocc.no/atc_ddd_index/Accessed January 20, 2011
   Google Scholar
• ShinfukuNTanCHPharmacotherapy for schizophrenic inpatients in East Asia: changes and challengesInt Rev Psychiatry200820546046819012132
   PubMed Web of Science ®Google Scholar
• LeuchtSKomossaKRummel-KlugeCA meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophreniaAm J Psychiatry2009166215216319015230
   PubMed Web of Science ®Google Scholar
• OkumuraYItoHKobayashiMMayaharaKMatsumotoYHirakawaJPrevalence of diabetes and antipsychotic prescription patterns in patients with schizophrenia: a nationwide retrospective cohort studySchizophr Res20101191–314515220304611
   PubMed Web of Science ®Google Scholar